

Addressing High-Cost Claims Panel Session: Part One



Jennifer Cloutier Managing Director Innovu



Christine Hale, MD Vice President, Clinical Consulting Lockton Dunning Benefits Associates



Jordan Taradash, MPH CEO PeopleOne Health



Panel moderated by Chris Syverson, CEO, Nevada Business Group on Health





The Impact of High-Cost Claims

CHRIS SYVERSON

NEVADA BUSINESS GROUP ON HEALTH

MODERATOR

Rethinking How We Mitigate *HIGH-COST CLAIMS*

The Problem: Few (if any) employers have the size, resources or focus to address rapidly escalating high-cost claims. Since 2016, the number of health plan members with claims \$3M+ has doubled, heightening sustainability concerns. Elimination of annual and lifetime maximums through the Affordable Care Act and the dysfunction of the reinsurance market has made this a top priority for every employer, purchaser and market.

High-Cost Claims Defined:

- Unpredictable/infrequent for individual employers
- Claims costing \$50,000 or more per year
- · Cost outliers that are frequently lasered (i.e., stoploss insurance covers only the first year of claims, then will cover everything except that claim) Often for severe, debilitating disease conditions
- Strategies will vary based on duration of expenditures and quality or Facts about high-cost claimants quantity of options Limited Options Multiple Effective Options OF ALL HEALTH PLAN MEMBERS **51.2%** ARE HIGH-COST CLAIMANTS Hemophilia Spinal muscular atrophy ...but they make up 1/3 of total Multiple sclerosis Metastatic cancers health care spending Multiple myeloma Long-duration Duchenne muscular dystrophy Autoimmune Immune globulin (palliative) Treatment Cystic fibrosis Congenital anomalies (lifelong) End-stage renal disease (ESRD) Hereditary angioedema Spinal muscular atrophy Lymphoma Premature birth Neutrotrophic keratitis Short-duration Spine surgeries Transplant Treatment Immune globulin (therapeutic) Congenital anomalies Inherited retinal dystrophy Idiopathic pulmonary fibrosis (RPE65) Sepsis \$122,382 29x Trauma and burns EMPLOYER RX VALUE ACTION BRIEF Average member cost Average annual cost National Alliance Offers Tools to Build the 53% CHRONIC CONDITIONS 47% ACUTE CONDITIONS Bridge to Sustainability Mitigating High-cost Claims: A Closer Look at Hemophilia ACTION BRIEF
 - Employer Rx Value Report and Value Framework Infographic
 - Hospital Payment Strategies: Setting Price & Quality Expectations



"High-cost claims are the biggest threat to employersponsored healthcare coverage today. Only through collective employer action can these risks be mitigated."

Wellmark Blue@Work

Michael Thompson National Alliance President & CEO

Be Proactive, not Reactive

Specific Saving Strategies for High-Cost Medical Drugs Learn more: Achieving Accountability & Predictibility on the Medical Side of Drug Benefits

CLINICAL RIGOR

- Separation of dispensing/rebates from clinical functions
- Independent, expert clinical management
- Cost-effective step therapy, when appropriate
- Elimination of waste
- Same level of clinical rigor applied to to specialty drugs on medical side
- Longer term increased specialization

Contracting Strategies

- Deconflict PBM and medical carrier relationships (fiduciary compliant)
- Reduced/fixed markups for provider buy/bill drugs
- Outcomes-based drug pricing
- Specialty generics filled in retail, not at specialty pharmacy
- Payment amortization (pay-over-time)
- Hospital at home/telehealth
- Narrow networks
- More timely and transparent reporting
- Bill review/negotiation
- Longer term population-based hybrid contracts

COST-EFFECTIVE SOURCING

- Better align co-pay and patient assistance programs
- Unrestricted, competitive dispensing options and sources
- Site-of-care optimization for provideradministered drugs

Plan Design Strategies

Quantity limits

Specialty carve out

Step therapy

high-cost drugs

 Longer term – collective management & stewardship

All drug management under the pharmacy benefit

Dose rounding protocols (for injectables)

PA/pre-certification functions

More rigorous utilization management for

Preferred drug lists/formularies

Exclusions/coverage limitations

Leverage secondary coverage when available

Longer term - Steerage to improve quality,

Aligned financial incentives with plan participants

(e.g., spouse employer, Medicaid or Medicare)


appropriateness and reduce impact of middlemen

Integrate Core Pillars of Overall Risk and Cost Reduction

There is no one-size-fits-all approach to tackle the broad spectrum of high-cost claims; a combination of options is needed for each case




CONTINUOUSLY REEXAMINE PATIENT EDUCATION, INVOLVEMENT AND ACCOUNTABILITY TO ENSURE SUSTAINABLE PATIENT ENGAGEMENT




National Alliance of Healthcare Purchaser Coalitions | 1015 18th Street, NW, Suite 705 Washington, DC 20036 | (202) 775-9300 | nationalalliancehealth.org |twitter.com/ntlalliancehth | linkedin.com/company/national-alliance/

Integrate Core Pillars of Overall Risk and Cost Reduction

There is *no one-size-fits-all approach* to tackle the *broad spectrum of high-cost claims*; a combination of options is needed for each case



Three biggest threats to affordability are drug prices, high-cost claims, and hospital prices



Nearly 8 out of 10 employers consider drug prices, high-cost claims, and hospital prices a significant threat to affordability of employerprovided health coverage for employees and their families

Significant Threat Minor Threat No threat positive impact

What's Really Driving Employer Health Plan Costs?

0.6% of a population drives 35% of employers' spend High-cost claims are different

High-cost claimants are made up of cancers, complex newborns, COVID/ sepsis, specialty drugs and implants Specialty Medicines, especially injectables, are the fastest-growing driver of high-cost claimants

High-Cost Claimant Predictive Analytics can *sometimes* identify these individuals and target early interventions



Health care inflation is driven by price increases, not utilization, think new medical and Rx technologies.



Chronic conditions are the direct cause of less than a quarter of medical and pharmacy claims over \$50,000 (high-cost claims)



Stop Loss Market Overview 2022

Severity and frequency of catastrophic claims continue to increase. The market is hardening as a result

Cancer remains the **most costly** condition since 2010

COVID and Sepsis claims had significant increases. An increase in Mental/ Behavioral Health claims was also observed

Decreases continued in *Transplant* and Renal, likely due to better contracting and clinical management

Note: Due to a change in the methodology used to group conditions in this year's report, catastrophic cases in categories like cardiovascular, musculoskeletal, and neurological now appear in the top 10

CLAIM CONDITIONS


Stop-loss claim reimbursements

2021 Rank	4 Year Rank	Condition/Disease/Disorder	2021 Single Year Reimbursements	2018–2021 Reimbursements	Total payments
1	1	Malignant Neoplasm	\$294.9M	\$1.03B	38%
2	2	Leukemia, Lymphoma, Multiple Myeloma	\$117.0M	\$443.1M	30 70 Top 3
3	3	Cardiovascular	\$102.3M	\$389.4M	conditions
4	4	Orthopedics/Musculoskeletal	\$89.6M	\$297.5M	
5	5	Newborn/Infant Care	\$82.3M	\$287.0M	70%
6	6	Respiratory	\$65.0M	\$234.1M	Top 10 conditions
11	7	Urinary/Renal	\$57.5M	\$222.6M	
9	8	Neurological	\$61.2M	\$210.7M	
10	9	Gastrointestinal/Abdominal	\$59.3M	\$200.9M	
7	10	Sepsis	\$64.2M	\$182.4M	
13	11	Congenital Anomaly (structural)	\$41.9M	\$172.0M	
12	12	Physician Treatment	\$47.1M	\$143.1M	
17	13	Transplant	\$26.7M	\$127.8M	
14	14	Cerebrovascular	\$29.8M	\$98.7M	
16	15	Hemophilia/Bleeding	\$28.4M	\$96.3M	
19	16	Immune System	\$21.2M	\$87.5M	
15	17	Mental and Behavioral Health	\$28.5M	\$87.1M	
18	18	Malnutrition	\$23.1M	\$79.8M	
8	19	COVID-19	\$61.5M	\$75.4M	
21	20	Blood and Blood Forming Organsh-cost claims a	\$18.6M	\$72.0M	

Blood and Record Fundation 2022 High-cost claims and injectable drug trends analysis



Case Examples



The factors, and therefor solutions, for complex claims are numerous and varied



Data Discussion






What Data Does



- Identify Healthcare WasteQuantify & Target Savings
- Measure Results

Innovu Data Management Solutions




Population Risk Assessment

PDB Demo Client


Risk Overview



Risk Distribution



Current Period: Jan 22 - Nov 22 Previous Period: Jan 21 - Dec 21



High	Risk Men	nbers		нсс		Current	Future
Age	Gender	Relation	Risk	Prev	/Curr	Cost	Cost
51	Female	Spouse	10.0 🔺	0		\$176.7K	\$50K-100K
57	Male	Self	10.0 🔺	0	0	\$42.7K	\$10K-25K
25	Male	Child	10.0 🔺			\$568K	\$100K-175K
17	Male	Child	10.0 *	0	0	\$95K	\$50K-100K
48	Female	Spouse	10.0 -		•	\$159.7K	\$100K-175K
60	Female	Self	10.0 *	•	0	\$71.6K	\$50K-100K
54	Male	Self	10.0 -	0	•	\$102K	\$100K-175K
57	Female	Spouse	10.0 -		•	\$194.6K	\$175K-250K
65	Male	Self	10.0 🔺		•	\$204.4K	\$175-250K

Risk Scores

ne reconciled Member model has yo measures of risk:

Current Risk: The expected rist during the current 12-month period

Future Risk: The expected risk in the following 12 months

What is risk? The risk models describe penditures as a function of linical and demographic variants of the second s pected amount of expendit r each member given their

How is it scaled? These expenditures are scaled intr percentiles within an organization For example, a member with a risi score of 8.5 is in the 85th percentil f predicted health or their organizatio

ousands of Innovu-derive Demographic variables

Chronic condition exposure
Diagnoses (CCS categories)
Prescription claims history

- How is this different? We took a data-driven approach to risk estimation that allows our scores to vary in more dimensions and in a non-linear fashion.
- to other 'Diagnosis-and-Pharmacy' risk scores.

We utilize a member's entire medical history to estimate thei risk. This is in contrast to many competitors that only use data

sinnovu^{*}

The motivation for risk adjustment

Self-insured companies struggle to understand their employee's health as clearly as the expenditures they are liable for paying. Innovu's solution leverages machine learning to accurately translate these expenditures as a function of their population's underlying health. This allows our advisors to distinguish anticipated from unpredictable health expenditures and direct additional resources to the most vulnerable members.

Data-driven instead of hypothesis-driven features


Risk scores are used in a variety of contexts in the healthcare sector; most notably to transfer risk-adjusted payments between insurance pools under the Patient Protection and Affordable Care Act. Innovu's risk scores expand upon the hierarchical condition category model from the U.S. Department of Health and Human Services (HCC-HSS) by leveraging thousands of additional features from our canonical data model. For example, both the HSS-HCC model and traditional actuarial risk adjustments will fit a single coefficient in a generalized linear model in the presence of a chronic condition. This obscures variation that we would expect within a chronic condition over a patient's disease progression. Our approach novel in this field because we relaxed the assumption that diseases should be treated equally over their progression. Instead, we rely on years of healthcare claims to estimate the non-linear impact of disease exposure to future expenditures.

Ensembles over single models

The HCC-HSS model and traditional actuarial risk adjustments both describe variation in expenditures as a function of a member's health in the context of a single regression model. This is problematic because regressions optimize for average outcomes, not exceptional ones. Healthcare expenditures are notoriously skewed, and we find that around half of our client's healthcare expenditures can be attributed to the top 5% of claimants. Therefore we adopted an ensembling approach where we build separate models to describe the top and bottom half of the distribution of expenditures. This allows our risk adjustment to estimate different mechanisms that drive risk for the high-cost claimants.

Competitive risk adjustments

We compared our model's performance in a prospective validation region representing 30% of our data with the MARA model from Milliman as well as the MEG+CCM model from Truven Health Analytics. These metrics are largely equivalent across concurrent and prospective models with the exception of the area under the ROC curve. We optimized our model specifically to address the risks of high-cost claimants and consequently identify the top 1% of members more reliably than other commercial risk adjusters.



Localized explanations

The HCC-HSS model and traditional actuarial risk adjustments both provide global explanations of the drivers of risk in a population. This is a useful context, but we have gone a step further to provide local explanations. This enables advisors to understand why a given member is at high risk. They can then refer them to an appropriate partner intervention program that addresses the individual's predicted needs.

12 Equivalent to tables 4.2.1 and 4.2.2 in 'Accuracy of Claims Based Scoring Models', Society of Actuaries 2016

- R², or the coefficient of determination, is a performance measure that describes the amount of variance in expenditures explained It ranges from 0 (no variance explained) to 1 (all variance explained)
- MAE, or mean absolute error, is a performance measure that describes the average amount of error in a risk score. It ranges from 0

ROC, or the receiver operator characteristic, is a performance measure that describes how well a risk score identifies the top 1% of members health expenditures. It ranges between 0.5 (random guess) to 1 (perfect identification).

High-Cost Claimant Overview

PDB Demo Client


High-Cost Claimant Overview

Current Period: Jan 22 - Nov 22 Previous Period: Jan 22 - Nov 22

Age	Gender	Relation	Primary Diagnosis	Enrolled	Risk	Medical	Pharmacy	Current Total	Previous Total
50	Female	Spouse	Encounter for antineoplastic chemotherapy	yes	8.9	\$845,160	\$86,725	\$931,884	\$378,915
50	Female	Self	Other nontraumatic intracerebral hemorrhage	yes	9	\$539,515	\$17,951	\$557,466	\$55,503
90	Male	Self	Squamous cell carcinoma of skin of scalp	yes	10	\$528,742	\$8,948	\$537,690	\$390,681
25	Male	Child	Hyp chr kidney disease w stage 5 chr k	yes	9.7	\$450,755	\$50,516	\$501,271	\$54,604
53	Female	Spouse	Malignant neoplasm of maxillary sinus	yes	9.9	\$247,025	\$6,464	\$253,489	\$262,459
22	Male	Child	Anxiety disorder, unspecified	yes	7.8	\$482	\$239,842	\$240,325	\$477
38	Female	Spouse	Other symptons and signs concerning fo	yes	9.9	\$170,549	\$12,553	\$183,101	\$49,124
58	Male	Self	Mantle cell lymphoma, unspecified site	yes	9.8	\$1,669	\$164,899	\$166,568	\$155,270
51	Female	Spouse	Benign intracranial hypertension	yes	10	\$152,713	\$11,354	\$164,068	\$73,023



Data Driven Point Solutions



ENHANCED HEALTHCARE:

COMMON SENSE AFFORDABLE NO DEDUCTIBLES





A MOVEMENT BASED ON A MISSION

HARRIS ROSEN President and COO

Rosen Hotels & Resorts

R

ZANE GATES, MD Co-Founder of PeopleOne Health

PEOPLEONE

DIRECT PRIMARY CARE

- Unlimited Utilization
- 30-60 minute appts
- 1 on 1 Relationship
- Improved Access
- Generic Rx (200+ Medications)
- Labs
- Care Coordination

INTEGRATED POPULATION HEALTH

- Registered Dietitian
- Health Coaches
- LCSW
- Clinical Pharmacist
- Specialty Consults
- Technology

DIRECT CONTRACT NETWORK


- Behavioral Health
- Physical Therapy
- Advanced Imaging
- Cardiology Testing
- Pulmonology Services
- Durable Medical Equipment



ENHANCED+ HEALTHCARE

For our members:

- <u>No</u> Copayments, deductibles or coinsurance
- <u>No</u> Paperwork or bills
- Pre-negotiated one rate system



Case Study 1



POPULATION

	2021		
	Other Insurance	PeopleOne Health	
Number of Employees	184	55	
Average Age	37.99	41.19	
Health Risk Score	1.21	1.29	
Members with one Chronic Condition	21.24%	27.85%	
Members with multiple Chronic Conditions	40.20%	31.65%	
Members with one or multiple Chronic Conditions	61.44%	59.49%	
Number of ER Visits per 1000	189.54	151.9	
Number of Urgent Care Visits per 1000	13.07	0	

PeopleOne Health has

- An older population
- A higher risk population
- A higher percentage of people with one chronic condition
- Almost the same percent of people with one or more chronic conditions
- PeopleOne Health better managed ER visits and Urgent Care visits
- With same day appointments, PeopleOne Health members never went to an Urgent Care



PLAN SPONSOR IMPACT

	2020	2021
	2020	
Number of Employees	228	239
Medical & Rx Claims Paid	\$2,192,623	\$1,846,530
Claims PEPY	\$9,617	\$7,726
	Detai	s 2021
	Detail	5 2021
	Other Insurance	PeopleOne Health
Number of Employees		
Number of Employees Medical & Rx Claims Paid	Insurance	Health
	Insurance 184	Health 55
Medical & Rx Claims Paid	Insurance 184 \$1,521,700 \$8,270	Health 55 \$324,831

Analysis of Claims Experience & Expenses

These are claims paid by the carrier

- Compared to 2020, the total PEPY has decreased from \$9,617 to \$7,726
- Evaluating further the impact of PeopleOne Health on claims experience
 - Members within the P1H program have a lower PEPY than those who are not using the P1H program
 - The variance is \$2,364 PEPY
 - The result is a claims reduction of \$130,025
 - This should be realized in the future renewals



HRA IMPACT

	Details 2021		
	Other Insurance	PeopleOne Health	
Number of Employees	184	55	
HRA Paid	\$207,536	\$43,814	
HRA PEPY	\$1,128	\$797	
Variance	\$33	1	
HRA Savings	\$18,2	221	

Analysis of HRA Impacts

These are direct Employer savings

- Those not in the P1H program are consuming their HRA savings at a higher rate compared to those who are in the P1H program
- The variance is \$331 PEPY
- The result is an average employer savings of about **\$18,221**



TOTAL SAVINGS

	Total Savings	PEPY Savings
Claims Reduction	\$130,025	\$2,364
HRA Savings	\$18,221	\$331
Employee Out of Pocket	\$24,376	\$443
Total Savings for P1H	\$172,622	\$3,138

Total Net Savings	\$54,359	\$988
PeopleOne Health Fees	\$118,263	\$2,150

Total Savings for Implementing P1H

The Out of Pocket savings is how much members saved. On average each **Employee saved \$443 per year**. Cash in their pocket.

- Claims reduction with increased care
- Lower utilization of HRA funds is Employer direct savings
- Total Savings \$172,622
- Total Net Savings removing the P1H fee is **\$54,359** or **\$988 per Employee**



Case Study 2



PeopleOne Health Independent Evaluation

- Client had the PeopleOne Health program assessed by an independent third-party
- Findings shared with us after they completed their assessment
- PeopleOne Health had higher risk population
- Due to this risk, they expected to see a \$6,005 PMPY
- Including all fees, P1H produced a \$4,195 PMPY
- Beating all other groups which averaged \$4,742 PMPY

	Regular Insurance	PeopleOne Health
Prospective Risk	1.100	1.380
Concurrent Risk	1.027	1.422
Expected PMPY	\$4,272	\$6,005
P1H Premium PMPY	N/A	\$1,464
P1H Outside Insurance Claims PMPY	N/A	\$2,731
Actual Total Cost PMPY	\$4,742	\$4,195



2022 Book Of Business Engagement Rate



* only clients enrolled in Prime for entire 2022 year



Confidential Information. Copyright © 2023 PeopleOne Health

Additional Stats

According to the Society of Actuaries, how much impact does a DPC model have on ER Utilization?

• Decrease by 40.5%

According to the Society of Actuaries, how much impact does a DPC model have on **Inpatient Admissions**?

• Decrease by 19.9%

According to the Society of Actuaries, an average DPC visit is 40 minutes with the patient. In a traditional fee for service model, how much time is spent per patient including the physician coding (non-face to face time)?

• 13 Minutes

According to the Society of Actuaries, how much impact does a DPC model have on **the Out of Pocket amount for a patient?**

• Decrease by 80%



Summary:

Know the threats Know your numbers Look for new opportunities

Take control of the future

